CNS Pharmaceuticals Inc. CNSP Archives

TuesdayApr 01, 2025 10:00 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advances TPI 287 for GBM, Ends 2024 with Strong Cash Position

CNS Pharmaceuticals (NASDAQ: CNSP) a biopharmaceutical company targeting brain and CNS cancers, reported a full-year 2024 net loss of $14.9 million, down from $18.9 million in 2023, due to reduced R&D spending. Despite Berubicin missing its primary endpoint in a glioblastoma multiforme (GBM) trial, the drug demonstrated safety and comparable efficacy, guiding future analysis. The company is shifting focus to TPI 287, a candidate with orphan drug designation and prior clinical data. With $6.5 million in cash at year-end and an additional $9.9 million raised post-period, CNS expects funding to last through Q1 2026. To view the full press release,…

FridayFeb 21, 2025 8:30 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at European Life Sciences CEO Forum

CNS Pharmaceuticals (NASDAQ: CNSP) announced that CEO John Climaco will present at the 18th Annual European Life Sciences CEO Forum in Zurich on Feb. 26, 2025, at 3:20 p.m. CET / 9:20 a.m. EST; management will also be available for one-on-one meetings with registered investors, and a video webcast of the presentation will be accessible on-demand through the conference presenters portal. To view the full press release, visit https://ibn.fm/J2yk5 About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central…

ThursdayFeb 20, 2025 8:30 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights 2025 Outlook at Virtual Investor Conference

CNS Pharmaceuticals (NASDAQ: CNSP) announced its participation in the Virtual Investor Top 5 for ‘25 On-Demand Conference, where CEO John Climaco outlined five key reasons for investors and industry peers to follow the company in 2025. The presentation focused on CNS Pharmaceuticals’ advancements in developing treatments for primary and metastatic brain and central nervous system cancers, emphasizing its strategic initiatives and clinical progress for the year ahead. To view the full press release, visit https://ibn.fm/wtayv About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic…

ThursdayDec 05, 2024 11:00 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Host Virtual Analyst & Investor Day on December 11

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company developing treatments for brain and central nervous system cancers, will host a Virtual Analyst & Investor Day on December 11 from 11:30 a.m. to 1 p.m. ET. The event will feature presentations by the company’s leadership team, including CEO John Climaco, Chief Medical Officer Dr. Sandra Silberman, and VP of Clinical Operations Zena Muzyczenko, alongside key opinion leaders Dr. Michael Weller, Dr. Samuel Goldlust, and Dr. Erin Dunbar. Discussions will focus on glioblastoma multiforme (“GBM”), updates on the clinical development of Berubicin, and regulatory strategies for the company’s second asset, TPI 287. A…

FridayNov 15, 2024 9:30 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advances Glioblastoma Treatment with Berubicin Amid Strong Financial Position

CNS Pharmaceuticals (NASDAQ: CNSP) reported Q3 2024 financial results and highlighted clinical advancements, including the ongoing potentially pivotal trial of Berubicin, a targeted chemotherapy for recurrent glioblastoma multiforme (“GBM”). Enrollment of 252 patients was completed, with primary analysis data expected in the first half of 2025. Berubicin, which crosses the blood-brain barrier, has received Fast Track and Orphan Drug Designations from the FDA. The company also licensed TPI 287, a late-stage candidate for brain malignancies, with plans for FDA engagement on future studies. CNS ended the quarter with $7.0 million in cash and additional funding, ensuring operations through Q2 2025.…

FridayNov 01, 2024 9:35 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Granted Nasdaq Extension for Compliance

CNS Pharmaceuticals (NASDAQ: CNSP) announced that it received an exception from the Nasdaq Hearings Panel, granting the company until March 11, 2025, to meet the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). This extension allows CNS additional time to regain compliance and maintain its listing status. To view the full press release, visit https://ibn.fm/1fuW5 About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and…

TuesdayOct 08, 2024 12:30 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Featured in Fireside Chat at 2024 Healthcare Virtual Summit

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be participating in the upcoming 2024 Healthcare Virtual Summit. The summit, which is presented by Maxim Group LLC, is scheduled for Oct. 16, 2024. According to the announcement, CNS Pharmaceuticals CEO John Climaco will be part of a fireside chat, slated to begin at 4 p.m. ET during the one-day event. In addition to the fireside chat, the summit will include presentations, interactive discussions and topical industry panels with an array of biotechnology,…

MondaySep 23, 2024 11:20 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at the 24th Annual Biotech in Europe Forum

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that CEO John Climaco will present at the 24th Annual Biotech in Europe Forum. The presentation is scheduled for Wednesday, September 25, 2024, at 1:55 p.m. CEST in Basel, Switzerland. Additionally, management will participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. To view the full press release, visit https://ibn.fm/KPZOu About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing…

WednesdaySep 04, 2024 3:25 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Slated to Present at H.C. Wainwright 26th Annual Global Investment Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be participating in the upcoming H.C. Wainwright 26th Annual Global Investment Conference. The event is slated for Sept. 9–11, 2024, in New York. According to the announcement, CEO John Climaco will present at the event; his presentation will be available as an on-demand video webcast beginning Sept. 9 at 7 a.m. ET. Climaco will also be available to participate in one-on-one meetings. To view the on-demand webcast, visit https://ibn.fm/gaP8o To view the full…

ThursdayAug 15, 2024 11:51 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Publishes Q2 2024 Results

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today released its financial results for the second quarter ended June 30, 2024 (“Q2 2024”). The company also discussed the clinical development progress of Berubicin, its lead program, and TPI 287, its recently in-licensed abeotaxane for the treatment of brain malignancies. CNS Pharmaceutical expects to be able to release final topline data from its potentially pivotal trial of Berubicin in the first half of 2025. The trial is evaluating Berubicin in adult patients with…

Site Search

Company Search

Tag: CNS Pharmaceuticals Inc. CNSP